Trial reportPhotodermatology, photoimmunology & photomedicine2026
Clinical Efficacy of 5-Aminolevulinic Acid Photodynamic Therapy Combined With Interferon Spray in Treating Common and Plantar Warts.
Trial report in Photodermatology, photoimmunology & photomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundConventional treatments for common and plantar warts often have limited efficacy and high recurrence rates. 5-Aminolevulinic acid photodynamic therapy (5-ALA-PDT) has attracted increasing attention as an alternative therapeutic option for these lesions. This study investigated the potential of 5-ALA-PDT as an alternative treatment option for patients with refractory common and plantar warts.
objectiveTo explore the clinical efficacy of 5-ALA-PDT and recombinant human interferon alpha 2b (rhIFN-α2b) spray combination therapy against common and plantar warts.
methodsWe enrolled 104 patients with common or plantar warts and randomly assigned them to the intervention (5-ALA-PDT combined with rhIFN-α2b spray; n = 51) or control (cryotherapy; n = 53) group to compare treatment efficacy, recurrence rate, and adverse events.
resultsAfter three consecutive treatment cycles, the 4-week complete recovery and total effective rates were 90.20% and 96.08% in the intervention group, versus 62.26% (p = 0.002) and 77.36% (p = 0.013) in the control group. Recurrence rates were significantly lower in the intervention group at 8 weeks (2.17% vs. 24.24%), 12 weeks (4.35% vs. 33.33%), and 6 months (4.35% vs. 39.39%; all p < 0.05). All adverse events were mild to moderate and localized.
conclusion5-ALA-PDT combined with rhIFN-α2b spray exhibited superior clinical efficacy in treating common and plantar warts, significantly improving treatment efficacy, reducing medium-term recurrence, and demonstrating good safety and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.